Guided Therapeutics (GTHP) Return on Capital Employed (2012 - 2025)

Guided Therapeutics (GTHP) has 14 years of Return on Capital Employed data on file, last reported at 42.95% in Q4 2025.

• For the quarter ending Q4 2025, Return on Capital Employed fell 61.0% year-over-year to 42.95%; the trailing twelve-month figure through Dec 2025 stood at 42.95% (down 61.0% YoY), and the FY2025 full-year result was 44.88%, down 63.0% from the prior year.
• Return on Capital Employed climbed to 42.95% in Q4 2025, from 39.58% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 427.0% in Q1 2023 to a low of 22.15% in Q1 2021.
• A 5-year average of 97.87% and a median of 55.27% in 2021 frame the typical range for Return on Capital Employed.
• Across the five-year window, Return on Capital Employed jumped 36926 bps in 2023 and tumbled 34797 bps in 2024, its largest moves.
• Tracing GTHP's Return on Capital Employed over 5 years: stood at 60.65% in 2021, then soared by 339 bps to 266.45% in 2022, then sank by 57 bps to 113.83% in 2023, then plunged by 62 bps to 43.56% in 2024, then declined by 1 bps to 42.95% in 2025.
• Business Quant data shows GTHP's Return on Capital Employed at 42.95% in Q4 2025, 39.58% in Q3 2025, and 41.89% in Q2 2025.